Crestchem's September quarter was a severe contraction. Revenue fell to ₹3.06 crore from ₹9.26 crore in the prior quarter, while net profit plummeted to just ₹0.08 crore, raising concerns over demand and operational stability.
For a small-cap specialty chemical company like Crestchem, steady quarterly execution is the baseline for investor confidence. The September 2026 quarter shattered that premise with a collapse in both revenue and profitability, signaling either a severe operational disruption or a sharp demand evaporation.
The numbers tell a story of near-total contraction. Revenue fell 67% sequentially to ₹3.06 crore, while net profit plunged 91.5% to a mere ₹0.08 crore. The net profit margin compressed by 760 basis points to 2.6%.
Revenue & profit
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin
Metric
CurrentQ2 FY27
PreviousQ1 FY27
Period Ended
September 2026
June 2026
Revenue (₹ Cr)
3.06
9.26
Profit (₹ Cr)
0.08
0.94
Net Profit Margin
2.6%
10.2%
Why the bottom fell out
The research points to a dramatic revenue decline as the primary driver. MarketsMojo called it a "precipitous 66.95% decline," signaling severe operational disruptions or significant demand challenges. The company's product portfolio, including Caprylic/Capric Triglycerides, serves industrial applications susceptible to cyclical demand.
Critically, operating profit excluding other income turned negative at ₹-0.08 crore. According to MarketsMojo, this marked the lowest quarterly operating performance on record. The modest net profit was only possible due to other income of ₹0.19 crore, highlighting a worrying dependence on non-operating sources.
The market's verdict was swift
Investor disappointment was immediate and severe. Following the results announcement, MarketsMojo reported the stock price crashed 19.98%. The report also noted the company's proprietary investment score resulted in a "SELL" rating, with quality downgraded to "Below Average."
Despite the operational crisis, the balance sheet offers a buffer. The company maintains zero long-term debt and is effectively a net cash company, as per MarketsMojo. This provides management breathing room to address the issues without immediate solvency concerns.
The path ahead hinges on one quarter
Management has not provided public guidance, according to StockFin.ai. The entire investment thesis now rests on whether Q2 was a temporary aberration. MarketsMojo lists a revenue recovery in Q3 FY27 and a return to positive operating margins as the key positive catalysts to watch.
The upcoming Q3 results, expected in early February 2027, will be decisive. They must demonstrate whether this was a one-quarter demand shock or the beginning of a sustained downturn for this niche chemical player.
Key Points
Revenue collapsed 67% quarter-on-quarter to ₹3.06 crore, while net profit plunged 91.5% to ₹0.08 crore.
Operating profit turned negative; the reported net profit was supported entirely by other income.
The stock price fell nearly 20% post-results, reflecting severe investor disappointment over operational challenges.
A debt-free balance sheet provides financial stability, but the next quarter is critical to prove the setback is temporary.
“
Hexa Perspective
This quarter represents a fundamental break in Crestchem's story. A two-thirds drop in sales is not a minor miss; it points to a potentially broken link in its supply, demand, or production chain. The fact that profit was saved only by other income strips away any veneer of operational resilience.
The company's historically strong returns and clean balance sheet are now assets in a recovery play, not indicators of current health. Investors are right to price in high uncertainty. The burden of proof is entirely on management to show a credible rebound in the March quarter, or this may be re-rated as a much riskier proposition.
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.
Frequently asked questions
What were Crestchem's Q2 FY27 results?
Crestchem reported severely weak results for the September 2026 quarter. Revenue was ₹3.06 crore, a 67% drop from the previous quarter. Net profit plummeted 91.5% to ₹0.08 crore, with the net profit margin shrinking to 2.6% from 10.2% in Q1 FY27.
Why did Crestchem's Q2 FY27 revenue fall 67% sequentially?
Research from MarketsMojo suggests the dramatic revenue collapse signals either severe operational disruptions or significant demand challenges. The company's specialty nutrition chemicals serve industrial applications, making it susceptible to volatile cyclical demand patterns which may have softened sharply.
Why did Crestchem's net profit margin fall despite lower expenses?
While total expenses fell 61%, revenue fell even more sharply by 67%. This collapse in the top line destroyed operating leverage. MarketsMojo reported that operating profit turned negative at ₹-0.08 crore, and the small net profit of ₹0.08 crore was only due to other income of ₹0.19 crore.
Did Crestchem face a plant shutdown or supply chain issue in Q2 FY27?
The available research does not cite a specific plant shutdown or supply chain disruption. The reports attribute the severe revenue drop broadly to potential operational disruptions or demand challenges, but no single event is identified as the cause for the September 2026 quarter.
What guidance did Crestchem management provide for future quarters?
According to analysis from StockFin.ai, there is no public forward guidance or management commentary available from the latest filings. The company has not issued earnings forecasts or a strategic outlook, making the next quarterly results the key data point for investors.
What is Crestchem's current order book status?
The research snippets reviewed do not provide any information on Crestchem's order book status or visibility for Q3 and Q4 FY27. This lack of forward-looking data adds to the uncertainty following the severe quarterly contraction.
Does Crestchem have sufficient working capital after the weak quarter?
Yes, the balance sheet remains a strength. MarketsMojo notes Crestchem maintains a robust balance sheet with zero long-term debt and is effectively a net cash company. This financial cushion provides management room to address operational issues without immediate solvency concerns.
Did Crestchem's Q2 results beat or miss analyst estimates?
The results were a severe miss against any reasonable expectation. While specific analyst estimates aren't cited, MarketsMojo reported the stock price crashed 19.98% following the announcement, reflecting major investor disappointment over the sharp deterioration in all key metrics.
Have any brokerages changed their rating for Crestchem after Q2 FY27?
MarketsMojo's proprietary assessment resulted in a "SELL" rating for Crestchem following the Q2 FY27 results, with the company's quality grade downgraded to "Below Average." This reflects deep concerns over operational performance outweighing valuation appeal.
How did Crestchem's stock price react to the Q2 FY27 results?
The reaction was sharply negative. According to MarketsMojo, the stock price crashed 19.98% following the results announcement on November 5, 2026. This reflected immediate investor disappointment over the 91.5% profit decline and negative operating margins.
Crestchem Ltd Q2 FY27 results
Crestchem announced its Q2 FY27 (September 2026) results on November 5, 2026. Revenue was ₹3.06 crore, down 67% from the previous quarter. Net profit was ₹0.08 crore, down 91.5%. Operating performance turned negative, with the small profit supported by other income.
Crestchem Q2 FY27 profit
Crestchem's net profit for Q2 FY27 (September 2026) was ₹0.08 crore. This represents a severe 91.5% decline from the ₹0.94 crore profit reported in the June 2026 quarter (Q1 FY27).
Why did Crestchem profits plunge?
Crestchem's profits plunged 91.5% in Q2 FY27 primarily due to a catastrophic 67% drop in revenue. The collapse in sales destroyed operating leverage, turning operating profit negative. The reported small net profit was only possible because of other income, as noted by MarketsMojo.
Crestchem revenue Q2 FY27
Crestchem's revenue for the second quarter of FY27, ended September 2026, was ₹3.06 crore. This is a precipitous 67% decline from the ₹9.26 crore revenue reported in the preceding quarter (Q1 FY27).
